A method and apparatus for confining a plasma are provided herein. In one embodiment, an apparatus for confining a plasma includes a substrate support and a magnetic field forming device for forming a magnetic field proximate a boundary between a first region disposed at least above the substrate support, where a plasma is to be formed, and a second region, where the plasma is to be selectively restricted. The magnetic field has b-field components perpendicular to a direction of desired plasma confinement that selectively restrict movement of charged species of the plasma from the first region to the second region dependent upon the process conditions used to form the plasma.
|
1. Apparatus for confining a plasma, comprising:
a process chamber having a substrate support disposed therein;
a magnetic field forming device for forming a magnetic field proximate a boundary between a first region disposed at least above the substrate support, where a plasma is to be formed, and a second region, where the plasma is to be selectively restricted; and
a controller adapted to control the apparatus such that charged species of a plasma formed using a first set of process conditions is restricted by the magnetic field from moving from the first region into the second region and charged species of a plasma formed using a second set of process conditions can move through the magnetic field from the first region to the second region.
14. Apparatus for confining a magnetic field, comprising:
a process chamber having a first region where a plasma is to be formed and a second region where the plasma is to be selectively restricted;
a substrate support disposed within the process chamber;
a magnetic field forming device for forming a magnetic field proximate a boundary between the first and second regions; and
a controller adapted to control the apparatus such that charged species of a plasma formed using a first set of process conditions is restricted by the magnetic field from moving from the first region into the second region and charged species of a plasma formed using a second set of process conditions can move through the magnetic field from the first region to the second region.
22. Apparatus for confining a plasma, comprising:
a process chamber having a substrate support disposed therein;
one or more permanent magnets configured to form a magnetic field proximate a boundary between a first region disposed at least above the substrate support, where a plasma is to be formed, and a second region, where the plasma is to be selectively restricted; and
a controller adapted to control the apparatus such that charged species of a plasma formed in the first region using a first set of process conditions is restricted by the magnetic field from moving from the first region into the second region and charged species of a plasma formed in the first region using a second set of process conditions can move through the magnetic field from the first region to the second region.
2. The apparatus of
3. The apparatus of
4. The apparatus of
5. The apparatus of
6. The apparatus of
7. The apparatus of
8. The apparatus of
9. The apparatus of
10. The apparatus of
11. The apparatus of
12. The apparatus of
13. The apparatus of
15. The apparatus of
16. The apparatus of
17. The apparatus of
18. The apparatus of
19. The apparatus of
20. The apparatus of
21. The apparatus of
one or more magnets disposed about the process chamber and configured to control characteristics of the plasma.
|
1. Field of the Invention
Embodiments of the present invention generally relate to plasma-assisted processing of substrates, and more particularly, to magnetic confinement of a plasma in plasma-assisted substrate processing chamber.
2. Description of the Related Art
Plasma-assisted processing is a technique commonly used, for example, in the manufacture of semiconductor devices and integrated circuits. Such processing generally includes introducing a process gas into a chamber having a substrate, such as a semiconductor wafer, disposed therein and applying sufficient energy to the process gas to form a plasma over the substrate. The plasma contains dissociated and ionized components as well as neutral components that operate to assist the process being performed on the substrate (such as deposition, etching, and the like). Although the constituents of the plasma are beneficial for assisting or carrying out the process on the substrate, it is often undesirable for the plasma constituents to come into contact with other components within the process chamber, such as the substrate support, sidewalls, or lid of the chamber. As such, it is often desirable to try to contain or limit the plasma to a region directly over the substrate being processed.
This problem has been conventionally addressed by the use of mechanisms for physically confining the plasma in the desired area. For example, certain process chambers may contain baffles that physically constrain the plasma within a desired area. However, these baffles transfer the problem from one of the plasma contamination or attack of the process chamber to plasma attack or contamination of the baffles themselves. As such, the baffles become a consumable material that may contribute to particulate defects on the substrate and further require periodic maintenance or replacement. In addition, physical confinement of the plasma using baffles restricts the ability to pump out plasma effluent from the chamber, thereby further degrading process performance and potentially leading to substandard process throughput and increased substrate defects.
Therefore, a need exists for an improved method and apparatus for confining a plasma in a process chamber.
A method and apparatus for confining a plasma are provided herein. In one embodiment, an apparatus for confining a plasma includes a substrate support and a magnetic field forming device for forming a magnetic field proximate a boundary between a first region disposed at least above the substrate support, where a plasma is to be formed, and a second region, where the plasma is to be selectively restricted. The magnetic field has b-field components perpendicular to a direction of desired plasma confinement that selectively restrict movement of charged species of the plasma from the first region to the second region dependent upon the process conditions used to form the plasma.
In another embodiment, an apparatus for confining a plasma includes a process chamber having a first region where a plasma is to be formed and a second region where the plasma is to be selectively restricted. A substrate support is disposed within the process chamber. A magnetic field forming device is provided for forming a magnetic field proximate a boundary between the first and second regions. The magnetic field is adapted to restrict movement of charged species of a plasma formed under a first set of process conditions between the first and second regions, while not restricting movement of charged species of a plasma formed under a second set of process conditions between the first and second regions.
In another aspect of the invention, a method for confining a plasma includes providing a process chamber having a first region where a plasma is to be formed and a second region from which the plasma is to be selectively restricted; and creating a magnetic field having b-field components perpendicular to a direction from the first region to the second region, and having a configuration selected to restrict movement of charged species of a plasma from the first region to the second region when the plasma is formed under a first set of process conditions, and not restricting movement of charged species of the plasma from the first region to the second region when the plasma is formed under a second set of process conditions. A first process may be performed using a plasma formed with the first set of process conditions, such that movement of charged species of the plasma is restricted. A second process may also be performed using a plasma formed with the second set of process conditions, such that movement of charged species of the plasma is not restricted.
So that the manner in which the above recited features of the present invention can be understood in detail, a more particular description of the invention, briefly summarized above, may be had by reference to embodiments, some of which are illustrated in the appended drawings. It is to be noted, however, that the appended drawings illustrate only typical embodiments of this invention and are therefore not to be considered limiting of its scope, for the invention may admit to other equally effective embodiments.
Where possible, identical reference numerals are used herein to designate identical elements that are common to the figures. The images in the drawings are simplified for illustrative purposes and are not depicted to scale.
The present invention provides methods and apparatus for confining a plasma using a magnetic field. In addition, the present invention further contemplates providing a method and apparatus for process selective plasma confinement using a magnetic field. In one embodiment, the method and apparatus of the invention confines a plasma discharge by exposing the plasma periphery to a magnetic field with a component perpendicular to the direction of desired confinement. The strength, direction, and location of the field is selected such that it confines plasmas under a first subset of process conditions, and does not confine plasmas under a second subset of process conditions that differs from the first subset.
In the embodiment depicted in
A first power source 120 is coupled to an electrode (not shown) proximate the first region 110 of the chamber 100, such as a lid of the chamber, a gas distribution showerhead, an inductive coil disposed near the chamber lid, or the like. The first power source 120 (sometimes referred to as a “top source,” or a “source power”) is generally capable of producing a radio-frequency (RF) signal at a power and frequency suitable to form a plasma from a process gas disposed in the first region 110 of the chamber 100. In one embodiment, the first power source 120 is generally capable of producing up to 5,000 Watts of radio-frequency (RF) power (i.e., source power) at a tunable frequency of above about 100 MHz. In one embodiment, the first power source 120 is generally capable of producing up to about 5,000 Watts of RF power at a tunable frequency of between about 100 kHz-200 MHz.
A second power source 122 may be coupled to an electrode disposed in or below the substrate support 104. The second power source 122 (sometimes referred to as a “bias source”) is generally capable of producing up to about 5,000 W RF power (i.e., cathode bias power) at a tunable frequency of between about 50 kHz-13.6 MHz. Optionally, the second power source 122 may be a source of DC or pulsed DC power. Alternatively, the second power source 122 may comprise a dual-frequency RF power source (or two RF power sources), in which case the first power source 120 is optional. It is contemplated that the first power source 120 and the second power source 122 may be capable of producing more or less power and at greater or lesser frequencies.
Support systems 124 are also coupled to the process chamber 100. The support systems 124 include components used to execute and monitor pre-determined processes in the process chamber 100 (e.g., plasma-assisted etching, depositing, annealing, cleaning, and the like). Such components generally include various sub-systems (e.g., gas panel(s), gas distribution conduits, vacuum and exhaust sub-systems, and the like) and devices (e.g., additional power supplies, process control instruments, and the like) of the process chamber 100. These components are well known to those skilled in the art and are omitted from the drawings for clarity.
A magnetic field forming device 114 is provided for forming a magnetic field along a boundary between the first and second regions 110, 112 suitable for selectively at least partially confining, or restricting, movement of components of the plasma 108 between the first and second regions 110, 112 during processing. Magnetic confinement reduces the charge particle mobility of a plasma by exposing the charged particles to a magnetic field perpendicular to their velocity. This generates a force on the charged particle equal to:
{right arrow over (F)}=q({right arrow over (v)}×{right arrow over (B)}) (1)
where F is the force exerted, q is the charge on the particle, v is the particle velocity, and B is the magnetic field strength. Since the direction of the force is perpendicular to the velocity of the charged particle, the net effect is a reduction in charged particle mobility perpendicular to the magnetic field direction. Therefore, by designing magnetic fields such that they are perpendicular to the flow of charged particles to a region of the process chamber where plasma is not desired (e.g., the second region 112 of the chamber 100), the reduction in mobility results in some level of plasma confinement between the region upstream from and downstream from the magnetic field.
In one embodiment, the magnetic field forming device 114 may form a magnetic field that either partially or completely surrounds the substrate support 104. The magnetic field forming device 114 may also form a magnetic field that either partially or completely fills a region 118 disposed between a portion of the side substrate support 104 and the chamber body 102. The magnetic field provided by the magnetic field forming device 114 may be disposed predominantly within the second region 112 of the chamber 100. In one embodiment, the magnetic field provided by the magnetic field forming device 114 may further be disposed predominantly below a support surface of the substrate support 104. The magnetic field forming device 114 may be disposed within or without the process chamber 100 and may be integrated into various chamber components or be a separate apparatus. In the embodiment depicted in
In the embodiment depicted in
To reduce interference with processing of a substrate, the magnetic field provided by the magnetic field forming device 114 may be disposed predominantly along a periphery of the plasma, i.e., along the boundary between the first and second regions 110, 112 of the chamber. Accordingly, the magnets 116 or the magnetic field forming device 114 may be arranged such the magnetic field provided by the magnets 116 or the magnetic field forming device 114 is disposed predominantly within the second region 112 of the chamber 100 (for example, predominantly below a support surface of the substrate support 104). In one embodiment, an upper surface of the magnets 116 is disposed between about 0-4 inches below the support surface of the substrate support 104. In one embodiment, an upper surface of the magnets 116 is disposed about 4 inches below the support surface of the substrate support 104.
Optionally, one or more permanent magnets or electromagnets (not shown) may further be disposed about the chamber to facilitate control of characteristics of the plasma during processing (e.g., to control plasma formation, density, ionization, dissociation, sheath characteristics, and the like). The magnetic fields created by such magnets may be primarily disposed in the first region 110 of the chamber and may be controlled independent of the magnetic field formed by the magnetic field forming device 114. Examples of chambers having magnets for controlling the plasma during processing include the above-mentioned eMax™, MXP®, and ENABLER™ process chambers, available from Applied Materials, Inc.
A controller 130 is coupled to and controls the operation of the process chamber 100 (i.e., the support systems 124, power sources 120, 122, and the like). In some embodiments, the controller 130 may also control the magnetic field forming device 114 (such as when the magnetic field forming device 114 comprise electromagnets). The controller 130 may be a specific or general purpose computer generally containing a CPU 132, support circuits 134, and memory 136. A software routine 138 may reside in the memory 136 that, when executed, provides for operation and control of the process chamber 100 in accordance with the teachings disclosed herein.
Another example of an embodiment of the magnetic field forming device 114 is depicted in the
The magnets 116, 216 depicted in
The confinement, or restriction, of the charged species of the plasma does not affect neutral species, such as a neutral species 210, which may cross the magnetic field 200A, 200B into the second region 112 of the process chamber 100. As such, movement of neutral species may occur even in processes where confinement is strongly desired, such as during processes that utilize highly polymerizing chemistries—where confinement or restriction of polymer generation and deposition advantageously minimizes the need for cyclical chamber cleaning and increases the time between cleaning cycles.
Accordingly, although providing plasma confinement during some processes is beneficial, there are also processes where plasma confinement is not desired. For example, such as during chamber cleaning steps, where a polymer removal chemistry is used to return the chamber to a pristine state. During such processes, it is advantageous to allow the plasma to fill the entire chamber, for example, to allow the cleaning chemistry to fill the entire chamber to facilitate removal of any polymer that may have built up away from the processing region (e.g., in the second region 112 of the process chamber 100 shown in
Depending upon process parameters that affect the plasma (such as source power, bias power, source frequency, bias frequency, process gas selection, chamber pressure, chamber process volume, and the like) and/or process parameters that affect the magnetic field (such as magnet strength, field direction, location, geometry, number of magnets, and the like), the amount, or level, of confinement of the charged species of the plasma within the first region 110 may be controlled.
For example, one method to measure the level of magnetic field confinement is to measure the ion flux from the plasma 108 to the body 102 in the first region 110 and the second region 112 of the process chamber 100 (as shown in
Similar process maps may be created with respect to other process parameters that affect the plasma and/or the magnetic field. Alternatively or in combination, a three-dimensional process map may be constructed by the above approach performed with the magnetic field at varying strengths to extend the process window to include varying magnetic field strength in addition to the plasma-affective process parameters. In addition, other plasma parameters, such as process density, sheath voltage, electron temperature, process chemistry, and the like, can all be impacted by the volume of the plasma, which may be controlled by the plasma confinement mechanism disclosed herein. Accordingly, these parameters may also be mapped to determine process conditions desired for a particular process to further advantageously widen the process window for a plasma process chamber having the inventive plasma confinement apparatus.
Parameters for the two processes may be controlled as desired to obtain the selective plasma confinement depicted in
In another example, substrate processing typically occurs at a top source power between about 0 W-1000 W, and a bias power between about 500 W-5000 W. Plasma confinement is generally desired during such substrate processing to improve process performance. However, chamber cleaning processes typically occur at a source power of greater than about 2000 W and a bias power of between about 0 W-100 W. As discussed above, plasma confinement is generally not desired during chamber cleaning processes. Accordingly, using a process map such as that depicted in
Next, at step 604, a plasma may be formed in a first region of the chamber using a first set of process parameters, such that movement of charged species of the plasma from the first region to the second region is restricted. In one embodiment, the charged species are confined to an upper region of the chamber. In one embodiment, the first set of process parameters includes at least one of source power, bias power, source frequency, bias frequency, process gas selection, chamber pressure, and chamber process volume. In one embodiment, the first set of process parameters includes at least one of source power and bias power.
Next, at step 606, a second plasma may be formed in the first region of the chamber using a second set of process parameters, such that movement of charged species of the plasma from the first region to the second region is not restricted. In one embodiment, the charged species are not confined to the upper region of the chamber. In one embodiment, the second set of process parameters includes at least one of source power, bias power, source frequency, bias frequency, process gas selection, chamber pressure, and chamber process volume. In one embodiment, the second set of process parameters includes at least one of source power and bias power.
Thus, embodiments of methods and apparatus for process selective plasma confinement using a magnetic field have been provided. In one embodiment, the method and apparatus of the invention confines a plasma discharge by exposing the plasma periphery to a magnetic field with a component perpendicular to the direction of desired confinement. The strength, direction, and location of the field is selected such that it confines plasmas under a first set of process conditions, and does not confine plasmas under a second set of process conditions that differs from the first set.
While the foregoing is directed to embodiments of the present invention, other and further embodiments of the invention may be devised without departing from the basic scope thereof, and the scope thereof is determined by the claims that follow.
Shannon, Steven C., Lindley, Roger A., Stinnett, James A., Rui, Ying, Yousif, Imad, Drexel, Masao, Xiao, Ying
Patent | Priority | Assignee | Title |
10016338, | Mar 11 2013 | SIO2 MEDICAL PRODUCTS, LLC | Trilayer coated pharmaceutical packaging |
10189603, | Nov 11 2011 | SIO2 MEDICAL PRODUCTS, LLC | Passivation, pH protective or lubricity coating for pharmaceutical package, coating process and apparatus |
10201660, | Nov 30 2012 | SIO2 MEDICAL PRODUCTS, LLC | Controlling the uniformity of PECVD deposition on medical syringes, cartridges, and the like |
10363370, | Nov 30 2012 | SIO2 MEDICAL PRODUCTS, LLC | Controlling the uniformity of PECVD deposition |
10390744, | May 13 2009 | SIO2 MEDICAL PRODUCTS, LLC | Syringe with PECVD lubricity layer, apparatus and method for transporting a vessel to and from a PECVD processing station, and double wall plastic vessel |
10537273, | May 13 2009 | SIO2 MEDICAL PRODUCTS, LLC | Syringe with PECVD lubricity layer |
10537494, | Mar 11 2013 | SIO2 MEDICAL PRODUCTS, LLC | Trilayer coated blood collection tube with low oxygen transmission rate |
10577154, | Nov 11 2011 | SIO2 MEDICAL PRODUCTS, LLC | Passivation, pH protective or lubricity coating for pharmaceutical package, coating process and apparatus |
10912714, | Mar 11 2013 | SIO2 MEDICAL PRODUCTS, LLC | PECVD coated pharmaceutical packaging |
11066745, | Mar 28 2014 | SIO2 MEDICAL PRODUCTS, LLC | Antistatic coatings for plastic vessels |
11077233, | Aug 18 2015 | SIO2 MEDICAL PRODUCTS, LLC | Pharmaceutical and other packaging with low oxygen transmission rate |
11116695, | Nov 11 2011 | SIO2 MEDICAL PRODUCTS, LLC | Blood sample collection tube |
11123491, | Nov 12 2010 | SIO2 MEDICAL PRODUCTS, LLC | Cyclic olefin polymer vessels and vessel coating methods |
11148856, | Nov 11 2011 | SIO2 MEDICAL PRODUCTS, LLC | Passivation, pH protective or lubricity coating for pharmaceutical package, coating process and apparatus |
11298293, | Mar 11 2013 | SIO2 MEDICAL PRODUCTS, LLC | PECVD coated pharmaceutical packaging |
11344473, | Mar 11 2013 | SIO2 MEDICAL PRODUCTS, LLC | Coated packaging |
11406765, | Nov 30 2012 | SIO2 MEDICAL PRODUCTS, LLC | Controlling the uniformity of PECVD deposition |
11624115, | May 12 2010 | SIO2 MEDICAL PRODUCTS, LLC | Syringe with PECVD lubrication |
11684546, | Mar 11 2013 | SIO2 MEDICAL PRODUCTS, LLC | PECVD coated pharmaceutical packaging |
11724860, | Nov 11 2011 | SIO2 MEDICAL PRODUCTS, LLC | Passivation, pH protective or lubricity coating for pharmaceutical package, coating process and apparatus |
11884446, | Nov 11 2011 | SIO2 MEDICAL PRODUCTS, LLC | Passivation, pH protective or lubricity coating for pharmaceutical package, coating process and apparatus |
9272095, | Apr 01 2011 | SIO2 MEDICAL PRODUCTS, LLC | Vessels, contact surfaces, and coating and inspection apparatus and methods |
9458536, | Jul 02 2009 | SIO2 MEDICAL PRODUCTS, LLC | PECVD coating methods for capped syringes, cartridges and other articles |
9545360, | May 09 2012 | SIO2 MEDICAL PRODUCTS, LLC | Saccharide protective coating for pharmaceutical package |
9554968, | Mar 11 2013 | SIO2 MEDICAL PRODUCTS, LLC | Trilayer coated pharmaceutical packaging |
9572526, | May 13 2009 | SIO2 MEDICAL PRODUCTS, LLC | Apparatus and method for transporting a vessel to and from a PECVD processing station |
9662450, | Mar 01 2013 | SIO2 MEDICAL PRODUCTS, LLC | Plasma or CVD pre-treatment for lubricated pharmaceutical package, coating process and apparatus |
9664626, | Nov 01 2012 | SIO2 MEDICAL PRODUCTS, LLC | Coating inspection method |
9764093, | Nov 30 2012 | SIO2 MEDICAL PRODUCTS, LLC | Controlling the uniformity of PECVD deposition |
9863042, | Mar 15 2013 | SIO2 MEDICAL PRODUCTS, LLC | PECVD lubricity vessel coating, coating process and apparatus providing different power levels in two phases |
9878101, | Nov 12 2010 | SIO2 MEDICAL PRODUCTS, LLC | Cyclic olefin polymer vessels and vessel coating methods |
9903782, | Nov 16 2012 | SIO2 MEDICAL PRODUCTS, LLC | Method and apparatus for detecting rapid barrier coating integrity characteristics |
9937099, | Mar 11 2013 | SIO2 MEDICAL PRODUCTS, LLC | Trilayer coated pharmaceutical packaging with low oxygen transmission rate |
Patent | Priority | Assignee | Title |
5211825, | Sep 21 1990 | Hitachi, Ltd. | Plasma processing apparatus and the method of the same |
6126790, | May 22 1998 | CVC Products, Inc. | Method of magnetically orienting thin magnetic films with a multiple-coil electromagnet |
6322661, | Nov 15 1999 | Lam Research Corporation | Method and apparatus for controlling the volume of a plasma |
6361667, | Mar 18 1997 | Anelva Corporation | Ionization sputtering apparatus |
6562189, | May 19 2000 | Applied Materials, Inc | Plasma reactor with a tri-magnet plasma confinement apparatus |
20010032590, | |||
20030037880, | |||
20060081559, |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Nov 15 2006 | DREXEL, MASAO | Applied Materials, Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 018558 | /0643 | |
Nov 16 2006 | SHANNON, STEVEN C | Applied Materials, Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 018558 | /0643 | |
Nov 16 2006 | LINDLEY, ROGER A | Applied Materials, Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 018558 | /0643 | |
Nov 16 2006 | YOUSIF, IMAD | Applied Materials, Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 018558 | /0643 | |
Nov 17 2006 | RUI, YING | Applied Materials, Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 018558 | /0643 | |
Nov 17 2006 | XIAO, YING | Applied Materials, Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 018558 | /0643 | |
Nov 28 2006 | Applied Materials, Inc. | (assignment on the face of the patent) | / | |||
Apr 25 2007 | STINNETT, JAMES A | Applied Materials, Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 019652 | /0856 |
Date | Maintenance Fee Events |
Aug 21 2015 | REM: Maintenance Fee Reminder Mailed. |
Jan 10 2016 | EXP: Patent Expired for Failure to Pay Maintenance Fees. |
Date | Maintenance Schedule |
Jan 10 2015 | 4 years fee payment window open |
Jul 10 2015 | 6 months grace period start (w surcharge) |
Jan 10 2016 | patent expiry (for year 4) |
Jan 10 2018 | 2 years to revive unintentionally abandoned end. (for year 4) |
Jan 10 2019 | 8 years fee payment window open |
Jul 10 2019 | 6 months grace period start (w surcharge) |
Jan 10 2020 | patent expiry (for year 8) |
Jan 10 2022 | 2 years to revive unintentionally abandoned end. (for year 8) |
Jan 10 2023 | 12 years fee payment window open |
Jul 10 2023 | 6 months grace period start (w surcharge) |
Jan 10 2024 | patent expiry (for year 12) |
Jan 10 2026 | 2 years to revive unintentionally abandoned end. (for year 12) |